BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 34484486)

  • 1. Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(12):1-123. PubMed ID: 34484486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT.
    Heer R; Lewis R; Duncan A; Penegar S; Vadiveloo T; Clark E; Yu G; Mariappan P; Cresswell J; McGrath J; N'Dow J; Nabi G; Mostafid H; Kelly J; Ramsay C; Lazarowicz H; Allan A; Breckons M; Campbell K; Campbell L; Feber A; McDonald A; Norrie J; Orozco-Leal G; Rice S; Tandogdu Z; Taylor E; Wilson L; Vale L; MacLennan G; Hall E
    Health Technol Assess; 2022 Oct; 26(40):1-144. PubMed ID: 36300825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer.
    Lai LY; Tafuri SM; Ginier EC; Herrel LA; Dahm P; Maisch P; Lane GI
    Cochrane Database Syst Rev; 2022 Apr; 4():CD014887. PubMed ID: 35393644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
    Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
    Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1-year Results.
    Naito S; Algaba F; Babjuk M; Bryan RT; Sun YH; Valiquette L; de la Rosette J;
    Eur Urol; 2016 Sep; 70(3):506-15. PubMed ID: 27117749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Aminolevulinic Acid Hydrochloride (5-ALA)-Guided Surgical Resection of High-Grade Gliomas: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(9):1-92. PubMed ID: 32194883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skin Substitutes for Adults With Diabetic Foot Ulcers and Venous Leg Ulcers: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(7):1-165. PubMed ID: 34211616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
    Rose JB; Armstrong S; Hermann GG; Kjellberg J; Malmström PU
    BJU Int; 2016 Jun; 117(6B):E102-13. PubMed ID: 26305667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Valve Stenosis at Low Surgical Risk: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(14):1-148. PubMed ID: 33240455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary cost-consequence analysis of blue light cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.
    Klaassen Z; Li K; Kassouf W; Black PC; Dragomir A; Kulkarni GS
    Can Urol Assoc J; 2017 Jun; 11(6):173-181. PubMed ID: 28652875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(10):1-234. PubMed ID: 32284770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2019; 19(6):1-199. PubMed ID: 30873251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non-muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled Trial.
    Yu G; Rice S; Heer R; Lewis R; Vadiveloo T; Mariappan P; Penegar S; Clark E; Tandogdu Z; Hall E; Vale L
    Eur Urol Open Sci; 2023 Jul; 53():67-77. PubMed ID: 37441343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Home Narrowband Ultraviolet B Phototherapy for Photoresponsive Skin Conditions: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(12):1-134. PubMed ID: 33240453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blue versus white light for transurethral resection of non-muscle invasive bladder cancer.
    Maisch P; Koziarz A; Vajgrt J; Narayan V; Kim MH; Dahm P
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013776. PubMed ID: 34850382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
    O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
    BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized trials.
    Sari Motlagh R; Mori K; Laukhtina E; Aydh A; Katayama S; Grossmann NC; Mostafai H; Pradere B; Quhal F; Schuettfort VM; Roshandel MR; Karakiewicz PI; Teoh J; Shariat SF; Fajkovic H
    BJU Int; 2021 Sep; 128(3):280-289. PubMed ID: 33683778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking.
    Mariappan P; Finney SM; Head E; Somani BK; Zachou A; Smith G; Mishriki SF; N'Dow J; Grigor KM;
    BJU Int; 2012 Jun; 109(11):1666-73. PubMed ID: 22044434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.